Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study

[1]  John O. Prior,et al.  Low-Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to Immunotherapy , 2021, Cancer discovery.

[2]  A. Markham.  Lurbinectedin: First Approval , 2020, Drugs.

[3]  S. Peters,et al.  Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial. , 2020, The Lancet. Oncology.

[4]  G. Ceresoli,et al.  Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16). , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  J. Qian,et al.  The M2 macrophage marker CD206: a novel prognostic indicator for acute myeloid leukemia , 2019, Oncoimmunology.

[6]  W. Fan,et al.  Identification of CD206 as a potential biomarker of cancer stem-like cells and therapeutic agent in liver cancer , 2019, Oncology letters.

[7]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[8]  S. Novello,et al.  NGR-hTNF in combination with best investigator choice in previously treated malignant pleural mesothelioma (NGR015): a randomised, double-blind, placebo-controlled phase 3 trial. , 2018, The Lancet. Oncology.

[9]  P. Allavena,et al.  Lurbinectedin reduces tumour-associated macrophages and the inflammatory tumour microenvironment in preclinical models , 2017, British Journal of Cancer.

[10]  Alberto Mantovani,et al.  Tumour-associated macrophages as treatment targets in oncology , 2017, Nature Reviews Clinical Oncology.

[11]  P. Allavena,et al.  Tumor-associated macrophages and anti-tumor therapies: complex links , 2016, Cellular and Molecular Life Sciences.

[12]  G. Ceresoli,et al.  Vinca alkaloids in the therapeutic management of malignant pleural mesothelioma. , 2015, Cancer treatment reviews.

[13]  P. Allavena,et al.  The interaction of anticancer therapies with tumor-associated macrophages , 2015, The Journal of experimental medicine.

[14]  Axel Hoos,et al.  Classification of current anticancer immunotherapies , 2014, Oncotarget.

[15]  Jeffrey W Pollard,et al.  Tumor-associated macrophages: from mechanisms to therapy. , 2014, Immunity.

[16]  G. Ceresoli,et al.  Vinorelbine in pemetrexed-pretreated patients with malignant pleural mesothelioma. , 2014, Lung cancer.

[17]  C. Lewis,et al.  Macrophage regulation of tumor responses to anticancer therapies. , 2013, Cancer cell.

[18]  M. Zucchetti,et al.  Role of macrophage targeting in the antitumor activity of trabectedin. , 2013, Cancer cell.

[19]  M. Nishimura,et al.  CD8+ tumor-infiltrating lymphocytes predict favorable prognosis in malignant pleural mesothelioma after resection , 2010, Cancer Immunology, Immunotherapy.

[20]  G. Zhu,et al.  Cutting Edge: Induction of B7-H4 on APCs through IL-10: Novel Suppressive Mode for Regulatory T Cells1 , 2006, The Journal of Immunology.

[21]  Gefeng Zhu,et al.  B7-H4 expression identifies a novel suppressive macrophage population in human ovarian carcinoma , 2006, The Journal of experimental medicine.

[22]  P. Allavena,et al.  Anti-inflammatory properties of the novel antitumor agent yondelis (trabectedin): inhibition of macrophage differentiation and cytokine production. , 2005, Cancer research.

[23]  J. V. van Meerbeeck,et al.  The role of gemcitabine in the treatment of malignant mesothelioma. , 2002, Seminars in oncology.